Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin

PURPOSE: Current therapy for lung cancer involves multimodality therapies. However, many patients are either refractory to therapy or develop drug resistance. KRAS and epidermal growth factor receptor (EGFR) mutations represent some of the most common mutations in lung cancer, and many studies have...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Girnun, Geoffrey D., Chen, Liang, Silvaggi, Jessica, Drapkin, Ronny, Chirieac, Lucian R., Padera, Robert F., Upadhyay, Rabi, Vafai, Scott B., Weissleder, Ralph, Mahmood, Umar, Naseri, Elnaz, Buckley, Stephanie, Li, Danan, Force, Jeremy, McNamara, Kate, Demetri, George, Spiegelman, Bruce M., Wong, Kwok-Kin
Médium: Artigo
Jazyk:Inglês
Vydáno: 2008
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2696122/
https://ncbi.nlm.nih.gov/pubmed/18927287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-1128
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky